Pathkey.ai Limited · ASX:PKY
Pathkey.ai — Investor Presentation (February 2021)
17 slides from Pathkey.ai's investor presentation, Feb 25, 2021
Slide 1: Half Year Investor Update
Half Year Investor Update Feb 2021
Slide 2: Disclaimer
Disclaimer This presentation is a general overview only and does not purport to contain all the information that may be required to evaluate an This presentation has been prepared by Opyl Limited (“Opyl”). investment in Opyl. The information in this presentation is Each recipient of this presentatio
Slide 3: Leaders in market intelligence and digital solutions in healthcare
Company Leaders in market intelligence and digital solutions in healthcare Taking the guesswork out of lifesciences opyl half year investor update 2021 | company 03
Slide 4: Overview
Overview Social Listening Strategy & Management Harnessing the value of public social media to identify, analyse, influence and improve health outcomes Augmenting sales strategies, creating specialist content, managing brands online Social Artificial Media Intelligence Clinical Trial Clinical Trial
Slide 5: Highlights
Highlights Overview Opyl delivers maiden profit Strenthened the Opyl Board with the appointment of Mark Ziirsen 33% increase in client revenue Improved cash position for Q2, with a net Priority on readying clinical trial recruitment cash balance of $730k solutions for full market launch in Q4 Signif
Slide 6: Highlights
Highlights R&D update Operations update Successfully delivered a major data trial evaluating Social media insights projects growing in client 475 COVID19 vaccine and therapeutics candidates revenue. This service offering is a key revenue to identify those most likely to complete and gain stream at p
Slide 7: HY2021 results
HY2021 results 33% 100% $748K increase retainers in committed in client re-signed by Covid contracts revenue affected clients for 2021 Finance & Operations Total client revenue up by 33% compared to R&D investment up by 24% and delivering to plan corresponding period in 2020, largely due to scale al
Slide 8: HY2021 results
HY2021 results 3 strategic focus on advancing platform sales from client services new hires roll out up 33% Finance & Operations Opyl team adapted easily to COVID19 government Focus on identifying government grant opportunities imposed social distancing and infection control to support late-stage pl
Slide 9: HY2021 results: Clinical trial recruitment platform
HY2021 results Clinical trial In-house recruitment social media platform scheduled marketing to go live Q3/Q4 team Research & development Clinical trial recruitment platform & services Web-enabled recruitment platform with the capacity to collect data on patients, healthcare providers and Highest de
Slide 10: HY2021 results: Clinical trial protocol prediction platform
HY2021 results 2nd major clinical trial Disruptive predictive software with efficiency potential for platform alternative markets Research & development Clinical trial protocol design/ prediction platform Commenced working with clinical trial design subject matter experts Successfully delivered COVI
Slide 11: Clients
Clients opyl half year investor update 2021 | CLIENTS 11
Slide 12: Leadership
Leadership Michelle Gallaher Dr Julian Chick Marat Basyrov Mark Ziirsen Chief Executive Officer Chairman Non Executive Officer Non Executive Officer Michelle has over 25 years of experience in Julian brings expertise in leading public life Marat is an recognised technology Mark is an experienced non
Slide 13: The year ahead
The year ahead Clinical trial recruitment Clinical trial protocol design and platform and service milestones prediction platform milestones Clinical trial recruitment platform launch - Continue to work with subject matter experts to end March/ Q3 2021 increase protocol variables in the algorithm fro
Slide 14: The year ahead
The year ahead Operations & financial performance Continue to drive growth in client revenue outcomes Annual review of huumun alliance (Feb 2021) with focus on expanding revenue-generating projects Expected continued growth in social media insights and new client acquisition projects and further ref
Slide 15: Milestones
Milestones DEC 2019 FEB 2020 MAY 2020 SEP 2020 DEC 2020 MAR 2021 MAY 2021 JUN 2021 Opyl launch Clinical trial huumun alliance COVID19 major Opyl service Clinical trial Clinical trial 3rd major data trial predictor delivers first data trial validate team expands recruitment recruitment planned for cl
Slide 16: Summary
Summary Leaders in social media intelligence - Scale strategy in play via alliance Stable specialist workforce delivering clear strategic target addressing a market agreements with huumun and looking services and revenue with 12 months gap providing stability, bringing target for more to support cli
Slide 17: opyl.com.ai | info@opyl.ai
Opyl opyl.com.ai | info@opyl.ai ©9000